https://scholars.lib.ntu.edu.tw/handle/123456789/632669
標題: | Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial | 作者: | JYH-MING LIOU YU-JEN FANG CHIEH-CHANG CHEN Bair, Ming-Jong Chang, Chi-Yang YI-CHIA LEE MEI-JYH CHEN CHIEN-CHUAN CHEN Tseng, Cheng-Hao Hsu, Yao-Chun Lee, Ji-Yuh Yang, Tsung-Hua Luo, Jiing-Chyuan Chang, Chun-Chao Chen, Chi-Yi Chen, Po-Yueh CHIA-TUNG SHUN WEN-FENG HSU Hu, Wen-Hao YEN-NIEN CHEN Sheu, Bor-Shyang Lin, Jaw-Town Wu, Jeng-Yih El-Omar, Emad M MING-SHIANG WU |
關鍵字: | GASTRIC-CANCER; SEQUENTIAL THERAPY; INFECTION; ERADICATION; METAANALYSIS; CLARITHROMYCIN; RESISTANCE; EFFICACY; METRONIDAZOLE; ESOMEPRAZOLE | 公開日期: | 12-十一月-2016 | 出版社: | ELSEVIER SCIENCE INC | 卷: | 388 | 期: | 10058 | 起(迄)頁: | 2355 | 來源出版物: | Lancet (London, England) | 摘要: | Whether concomitant therapy is superior to bismuth quadruple therapy or 14-day triple therapy for the first-line treatment of Helicobacter pylori infection remains poorly understood. We aimed to compare the efficacy and safety of 10-day concomitant therapy, 10-day bismuth quadruple therapy, and 14-day triple therapy in the first-line treatment of H pylori. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/632669 | ISSN: | 0140-6736 | DOI: | 10.1016/S0140-6736(16)31409-X |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。